他莫昔芬序贯依西美坦治疗绝经后内分泌敏感性乳腺癌患者的安全性

Safety of sequential exemestane therapy after 2-3 years' tamoxifen treatment in postmenopausal women with hormone sensitive breast cancer

目的:评估依西美坦治疗经他莫昔芬辅助治疗2～3年后的绝经后雌激素受体阳性乳腺癌妇女的安全性。方法:回顾性分析50例雌激素受体阳性的绝经后乳腺癌妇女,这些患者均在接受2～3年他莫昔芬治疗后换用依西美坦治疗。对这些患者进行随访,并评价疗效及其安全性。结果:中位随访时间为31个月,全部50例患者均未出现病理学或影像学证实的复发、转移或第二原发肿瘤,也无患者因任何原因而死亡。不良反应主要为关节痛(8%),其他不良事件发生率较低。依西美坦对血常规及生化指标无明显影响,患者基本可耐受治疗。结论:绝经后雌激素受体阳性的乳腺癌患者应用他莫昔芬转换依西美坦方案较为安全,最常见的不良反应为关节痛。

Objective：To evaluate the safety of sequential exemestane therapy after 2-3 years＇ tamoxifen treatment in postmenopausal women with hormone sensitive breast cancer.Methods：Fifty eligible postmenopausal patients with estrogen receptor-positive breast cancer who were disease-free for 2-3 years of tamoxifen followed by exemestane were reviewed retrospectively.The efficacy and safety of exemestane were examined.Results：After a median follow-up of 31 months,no recurrences,metastases,second primary cancers or deaths due to any causes occurred among the 50 patients.Exemestane was generally well tolerated.The key adverse event observed was arthralgia with an incidence rate of 8%.There was little effect on lipid metabolism,and the exemestane was well tolerated.Conclusion：This study suggests that exemestane can be safely administered sequentially after tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer,with a common side effect of arthralgia.